Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05156788
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-08-15
First Post:
2021-09-30
Brief Title:
TislelizumabAnti PD-1 Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable Locally Advanced Biliary Tract Cancer
Sponsor:
Organization:
Shanghai Zhongshan Hospital
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
40
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: